Botulinum A Toxin/Dimethyl Sulfoxide Bladder Instillations for Women With Refractory Idiopathic Detrusor Overactivity: A Phase 1/2 Study

August 2009
Mayo Clinic Proceedings;Aug2009, Vol. 84 Issue 8, p702
Academic Journal
We completed a phase 1/2 trial to evaluate the safety and potential efficacy of direct intravesical instillation of a botulinum type A toxin/dimethyl sulfoxide (DMSO) solution for treatment of idiopathic detrusor overactivity in women. Twenty-five women with medication-resistant, urodynamic-confirmed idiopathic detrusor overactivity were enrolled. A total of 9 patients were treated in phase 1 of the study. Three patients were given a 66% dosing of solution; 22 patients received the full 300 units of botulinum toxin and 50 mL of DMSO (50% concentration). Adverse effects, 24-hour pad weights, episodes of incontinence, postvoid residuals, and scores on the Blalvas-Groutz anti-incontinence scale, Indevus Urgency Severity Scale, Incontinence Impact Questionnaire-short form, and Urogenital Distress inventory (6 items) questionnaire were recorded at baseline, 1 month, and 3 months after instillation. No serious adverse effects or clinically important increases in postvoid residual occurred. Among the 21 women who completed phase 2 of the study, the median number of incontinent episodes decreased from 4 at baseline to 2 at 1 month (P=.004) and increased to 4 at 3 months (P=.81). Median scores Improved from baseline to 1 month on the Incontinence Impact Questionnaire (from 13 to 7; P=.007) and Urogenital Distress inventory (from 10 to 5; P=.003). Although 11 women (52%) reported severe urgency based on the Indevus Urgency Severity Scale at baseline, only 1 (5%; P<.001) and 3 (14%; P=.004) women reported severe scores at 1 and 3 months, respectively. Direct instillation of botulinum toxin/DMSO solution is safe. its promising clinical effect warrants further evaluation in a randomized, placebo-controlled phase 3 setting.


Related Articles

  • Botulinum toxin B shows rapid onset, efficacy in OAB. Gagnon, Louise // Urology Times;12/1/2005, Vol. 33 Issue 15, p16 

    The article discusses a study conducted by British researcher James Malon-Lee and colleagues, who found that botulinum toxin type B appears to be more effective for the treatment of over-active bladder, although the agent has a short duration of action. The 20 participants in the study were...

  • Botulinum Toxin Type A for the Prophylactic Treatment of Chronic Daily Headache: A Randomized, Double-Blind, Placebo-Controlled Trial. Silberstein, Stephen D.; Stark, Stuart R.; Lucas, Sylvia M.; Christie, Suzanne N.; DeGryse, Ronald E.; Turkel, Catherine C. // Mayo Clinic Proceedings;Sep2005, Vol. 80 Issue 9, p1126 

    OBJECTIVES: To identify a treatment-responsive population for botulinum toxin type A (BoNTA) and to evaluate the safety and efficacy of 3 different doses of BoNTA as prophylactic treatment of chronic daily headache (CDH). PATIENTS AND METHODS: A randomized, double-blind, placebo-controlled study...

  • Instillation 'cocktail' appears safe, effective in OAB. Tennant, Scott // Urology Times;7/1/2009, Vol. 37 Issue 8, p10 

    The article focuses on the result of a phase I and II trial conducted by researchers at Mayo Clinic in Jacksonville, Florida. It reveals that direct instillation of a solution that contains botulinum toxin A (Botox) and dimethyl sulfoxide (DMSO [Rimso-50]) may cure women with voiding dysfunction...

  • Cocrystal structure of synaptobrevin-II bound to botulinum neurotoxin type B at 2.0 Ã… resolution. Hanson, Michael A.; Stevens, Raymond C. // Nature Structural Biology;Aug2000, Vol. 7 Issue 8, p687 

    Botulinum neurotoxin serotype B is a zinc protease that disrupts neurotransmitter release by cleaving synaptobrevin-II (Sb2), one of three SNARE proteins involved in neuronal synaptic vesicle fusion. The three-dimensional crystal structure of the apo botulinum neurotoxin serotype B catalytic...

  • Uses of botulinum toxin injection in medicine today. Munchau, A.; Bhatia, K. P. // BMJ: British Medical Journal (International Edition);01/15/2000, Vol. 320 Issue 7228, p161 

    Discusses the uses of botulinum toxin injection in modern medicine. Mode of action; Rationale for treatment with botulinum neurotoxin; Side effects of the toxin; Indications for treatment.

  • The many faces of botox. Cohen, Sharon; Kallen, Ben // Shape;Jul2004, Vol. 23 Issue 11, p93 

    Reports on various uses of botulinum toxin.

  • Editors' Response to Johnson. Hooper, David C.; Hirsch, Martin S. // Journal of Infectious Diseases;Sep2014, Vol. 210 Issue 6, p993 

    A response from the editor related to articles regarding the purported new botulinum neurotoxin serotype H published in a 2014 issue is presented.

  • Intravesical botulinum toxin type A in chronic interstitial cystitis: Results of a pilot study. Ramsay, A. K.; Small, D. R.; Conn, I. G. // Surgeon (Edinburgh University Press);Dec2007, Vol. 5 Issue 6, p331 

    Aim: To assess the efficacy of intravesical botulinum toxin type A (BTX-A) in interstitial cystitis (IC). Methods: Eleven patients with IC were injected with BTX-A. Primary outcome measures were: Bristol Female Lower Urinary Tract Symptom Score, Kings Health Questionnaire and 24-hour...

  • Botulinum Toxin A (Botox® Cosmetic): A Review of its Use in the Treatment of Glabellar Frown Lines. Frampton, James E.; Easthope, Stephanie E. // American Journal of Clinical Dermatology;2003, Vol. 4 Issue 10, p709 

    Botox[sup ®] Cosmetic (Botox[sup ®]) is a formulation of the neuromuscular blocking agent botulinum toxin type A (BTX-A). When injected into hyperactive corrugator superciliaris and/or procerus muscles of the face that predominantly control frowning, Botox[sup ®] produces a transient...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics